Alzinova AB (SE:ALZ)

:ALZ

ALZ

Alzinova AB

RESEARCH TOOLSreports

Want to see SE:ALZ full AI Analyst Report?

Alzinova AB (ALZ) Price & Analysis

2 Followers

ALZ Stock Chart & Stats

kr0.82

-kr0.14(-4.96%)

At close: Mar 06 4:00 PM EST

kr0.82

-kr0.14(-4.96%)

Day’s Range― - ―

52-Week Rangekr0.42 - kr2.28

Previous CloseN/A

Volume98.89K

Average Volume (3M)655.64K

Market Cap

kr68.57M

Enterprise Valuekr48.33M

Total Cash (Recent Filing)kr319.00K

Total Debt (Recent Filing)kr800.00K

Price to Earnings (P/E)―

Beta0.34

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding154,961,400

10 Day Avg. Volume664,473

30 Day Avg. Volume655,642

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.63

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Debt / Strong Balance SheetThe company's balance sheet shows very low debt and sizable equity, providing durable financial flexibility for a development-stage biotech. This reduces bankruptcy risk, supports continuing R&D financing, and enhances ability to negotiate partnerships or structured financings without immediate solvency pressure.

Platform Therapy Focus (ALZ-101)Alzinova’s ALZ-101 vaccine platform targets toxic forms of amyloid‑beta, representing a disease‑modifying approach in Alzheimer’s. A successful platform can generate multiple assets (vaccines and antibodies), increasing optionality and long‑term partner interest across development and commercialization stages.

Clear Monetization Pathway Via PartnershipsThe stated business model relies on out‑licensing, co‑development, and collaboration deals, a durable route for pre‑commercial biotechs to monetize assets. This reduces capital intensity for commercialization and aligns incentives with larger pharma partners for regulatory and market access execution.

Bears Say

Persistent Negative Cash FlowOperating and free cash flows have been consistently negative, indicating ongoing cash burn without internal self‑funding. This structural funding requirement increases dilution risk, forces dependency on capital markets or deals, and constrains ability to sustain multi‑year clinical development independently.

Collapsed Revenue And Widening LossesRevenue has fallen to near‑zero while operating and net losses have widened, reflecting no commercial revenue stream and escalating development costs. The deteriorating income statement reduces runway visibility and heightens execution risk until a partnering deal or clinical de‑risking event occurs.

Very Small HeadcountA team of five implies limited internal scientific, regulatory, and operational capacity, increasing reliance on external CROs and partners. This constrains in‑house ability to scale programs, manage multiple trials or regulatory interactions, and can slow program timelines or increase external spend.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.42 and its highest was kr2.28 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr68.57M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is May 20, 2026 which is in 19 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on Mar 25, 2026. The company reported -kr0.055 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.055.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 154,961,400 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.055 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.125%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.